Biofluid Biomarkers for Alzheimer's Disease

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2024 Apr 25

PMID 38659704

Authors

Sensen Wang

Sitan Xie

Qinpin Zheng

Zhihui Zhang

Tian Wang

Guirong Zhang

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a multifactorial neurodegenerative disease, with a complex pathogenesis and an irreversible course. Therefore, the early diagnosis of AD is particularly important for the intervention, prevention, and treatment of the disease. Based on the different pathophysiological mechanisms of AD, the research progress of biofluid biomarkers are classified and reviewed. In the end, the challenges and perspectives of future research are proposed.

References

Jia L, Qiu Q, Zhang H, Chu L, Du Y, Zhang J . Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement. 2019; 15(8):1071-1080. DOI: 10.1016/j.jalz.2019.05.002. View

Verberk I, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A . Combination of plasma amyloid beta and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther. 2020; 12(1):118. PMC: 7523295. DOI: 10.1186/s13195-020-00682-7. View

Schindler S, Bollinger J, Ovod V, Mawuenyega K, Li Y, Gordon B . High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019; 93(17):e1647-e1659. PMC: 6946467. DOI: 10.1212/WNL.0000000000008081. View

Goetzl E, Abner E, Jicha G, Kapogiannis D, Schwartz J . Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease. FASEB J. 2017; 32(2):888-893. PMC: 5888398. DOI: 10.1096/fj.201700731R. View

Visser P, Verhey F, Knol D, Scheltens P, Wahlund L, Freund-Levi Y . Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009; 8(7):619-27. DOI: 10.1016/S1474-4422(09)70139-5. View

Fleisher A, Chen K, Quiroz Y, Jakimovich L, Gutierrez Gomez M, Langois C . Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol. 2015; 72(3):316-24. PMC: 4355261. DOI: 10.1001/jamaneurol.2014.3314. View

Ashton N, Pascoal T, Karikari T, Benedet A, Lantero-Rodriguez J, Brinkmalm G . Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta Neuropathol. 2021; 141(5):709-724. PMC: 8043944. DOI: 10.1007/s00401-021-02275-6. View

Shui B, Tao D, Florea A, Cheng J, Zhao Q, Gu Y . Biosensors for Alzheimer's disease biomarker detection: A review. Biochimie. 2018; 147:13-24. DOI: 10.1016/j.biochi.2017.12.015. View

Decourt B, Sabbagh M . BACE1 as a potential biomarker for Alzheimer's disease. J Alzheimers Dis. 2011; 24 Suppl 2:53-9. PMC: 3313825. DOI: 10.3233/JAD-2011-110017. View

10.

Mroczko B, Groblewska M, Zboch M, Muszynski P, Zajkowska A, Borawska R . Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease. J Alzheimers Dis. 2014; 43(3):1031-7. DOI: 10.3233/JAD-141050. View

11.

Barthelemy N, Horie K, Sato C, Bateman R . Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. J Exp Med. 2020; 217(11). PMC: 7596823. DOI: 10.1084/jem.20200861. View

12.

Halliday M, Rege S, Ma Q, Zhao Z, Miller C, Winkler E . Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J Cereb Blood Flow Metab. 2015; 36(1):216-27. PMC: 4758554. DOI: 10.1038/jcbfm.2015.44. View

13.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006; 5(3):228-34. DOI: 10.1016/S1474-4422(06)70355-6. View

14.

Xiao M, Xu D, Craig M, Pelkey K, Chien C, Shi Y . NPTX2 and cognitive dysfunction in Alzheimer's Disease. Elife. 2017; 6. PMC: 5404919. DOI: 10.7554/eLife.23798. View

15.

Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlgren N . Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther. 2021; 13(1):68. PMC: 8005231. DOI: 10.1186/s13195-021-00804-9. View

16.

Blennow K, Hampel H . CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003; 2(10):605-13. DOI: 10.1016/s1474-4422(03)00530-1. View

17.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

18.

Liu P, Xie Y, Meng X, Kang J . History and progress of hypotheses and clinical trials for Alzheimer's disease. Signal Transduct Target Ther. 2019; 4:29. PMC: 6799833. DOI: 10.1038/s41392-019-0063-8. View

19.

Pankonin M, Sohi J, Kamholz J, Loeb J . Differential distribution of neuregulin in human brain and spinal fluid. Brain Res. 2009; 1258:1-11. DOI: 10.1016/j.brainres.2008.12.047. View

20.

Shao K, Shan S, Ru W, Ma C . Association between serum NPTX2 and cognitive function in patients with vascular dementia. Brain Behav. 2020; 10(10):e01779. PMC: 7559607. DOI: 10.1002/brb3.1779. View